Previous 10 | Next 10 |
2023-04-25 08:01:00 ET Biogen ( NASDAQ: BIIB ) stock is trading in the red premarket Tuesday after the company said it is discontinuing certain drug programs amid reporting its Q1 results, which beat estimates. Biogen said it will terminate its involvement in developing BI...
2023-04-25 07:03:28 ET Biogen ( NASDAQ: BIIB ): Q1 Non-GAAP EPS of $3.40 beats by $0.12 . Revenue of $2.46B (-2.8% Y/Y) beats by $120M . FY 23 outlook: Revenue to report mid-single digit decline vs FY22. Adj EPS of $15.00-$16.00 vs $15.76 For further deta...
2023-04-24 11:52:38 ET Biogen ( NASDAQ: BIIB ) is scheduled to announce Q1 earnings results on Tuesday, April 25th, before market open. The consensus EPS Estimate is $3.29 (-9.1% Y/Y) and the consensus Revenue Estimate is $2.34B (-7.5% Y/Y). Over the last 2 years, BIIB ...
2023-04-23 12:00:00 ET Biotech deal-making is on a roll, with more than $12B worth of transactions announced over the past week alone, and, according to industry observers, the trend is expected to continue in 2023, supported by macro and certain industry-specific factors. Days after Me...
2023-04-21 15:00:36 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
2023-04-21 13:30:41 ET The peak of earnings season progresses over the final full week of April. A host of Big Tech heavyweights will garner the most attention, although a wide variety of consumer staples, industrial and energy names are scheduled to provide earnings updates as well. Mi...
2023-04-20 14:00:00 ET When you think of biotech investing, you might focus on small companies that are years away from product revenue. They may eventually offer great rewards -- but at the moment, risk is high. If you're more of a cautious investor, that may not be your thing. That doesn'...
2023-04-17 16:35:34 ET Piper Sandler has upgraded Biogen ( NASDAQ: BIIB ) to overweight as it sees a "confluence of positive catalysts" in the near future, including robust uptake of Alzheimer's therapy Leqembi (lecanemab). The firm has upped its price target to $346 from $2...
2023-04-17 10:03:55 ET The net benefit of Biogen ( NASDAQ: BIIB ) and Eisai's ( OTCPK:ESALF ) Alzheimer's treatment Leqembi (lecanemab) is uncertain, and may even cause harm, according to a final evidence report from a key non-profit organization that evaluates medications...
2023-04-14 14:30:56 ET Earnings season heats up in mid-April with a host of earnings results due from the likes of Tesla ( NASDAQ: TSLA ), Netflix ( NFLX ), Johnson & Johnson ( JNJ ), Lockheed Martin ( LMT ), and a host of financial giants. Bank of America ( BAC ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...